Stifel Nicolaus Raises ClearPoint Neuro (NASDAQ:CLPT) Price Target to $25.00

ClearPoint Neuro (NASDAQ:CLPT - Free Report) had its price objective lifted by Stifel Nicolaus from $19.00 to $25.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities research analysts have also recently issued reports on the company. Lake Street Capital lifted their price objective on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a report on Tuesday, January 21st. B. Riley boosted their price target on ClearPoint Neuro from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th.

ClearPoint Neuro Stock Performance

Shares of ClearPoint Neuro stock traded down $1.11 on Tuesday, hitting $11.03. The company's stock had a trading volume of 389,895 shares, compared to its average volume of 215,993. The company has a market capitalization of $304.78 million, a price-to-earnings ratio of -15.99 and a beta of 0.97. ClearPoint Neuro has a 1 year low of $5.11 and a 1 year high of $19.22. The firm has a fifty day moving average price of $15.22 and a 200-day moving average price of $14.02.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The business had revenue of $7.77 million for the quarter, compared to analyst estimates of $8.23 million. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. As a group, analysts forecast that ClearPoint Neuro will post -0.66 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On ClearPoint Neuro

A number of institutional investors have recently added to or reduced their stakes in CLPT. Conway Capital Management Inc. purchased a new position in shares of ClearPoint Neuro during the 3rd quarter worth $1,586,000. JPMorgan Chase & Co. increased its position in ClearPoint Neuro by 58.7% during the third quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock worth $110,000 after purchasing an additional 3,612 shares during the last quarter. Barclays PLC raised its stake in ClearPoint Neuro by 24.3% during the third quarter. Barclays PLC now owns 5,674 shares of the company's stock worth $64,000 after purchasing an additional 1,109 shares during the period. Geode Capital Management LLC grew its stake in shares of ClearPoint Neuro by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 287,294 shares of the company's stock valued at $3,222,000 after buying an additional 4,170 shares during the period. Finally, Bradley Foster & Sargent Inc. CT purchased a new stake in shares of ClearPoint Neuro in the 4th quarter valued at approximately $871,000. Hedge funds and other institutional investors own 30.08% of the company's stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.